CL2014002557A1 - Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. - Google Patents

Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.

Info

Publication number
CL2014002557A1
CL2014002557A1 CL2014002557A CL2014002557A CL2014002557A1 CL 2014002557 A1 CL2014002557 A1 CL 2014002557A1 CL 2014002557 A CL2014002557 A CL 2014002557A CL 2014002557 A CL2014002557 A CL 2014002557A CL 2014002557 A1 CL2014002557 A1 CL 2014002557A1
Authority
CL
Chile
Prior art keywords
pyrazinone
cancer
kit
prevention
treatment
Prior art date
Application number
CL2014002557A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Dorsch
Hans-Peter Buchstaller
Ansgar Wegener
Gérard Moinet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2014002557A1 publication Critical patent/CL2014002557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014002557A 2012-03-28 2014-09-25 Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. CL2014002557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12002215 2012-03-28

Publications (1)

Publication Number Publication Date
CL2014002557A1 true CL2014002557A1 (es) 2014-12-19

Family

ID=48013911

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002557A CL2014002557A1 (es) 2012-03-28 2014-09-25 Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.

Country Status (31)

Country Link
US (1) US9120805B2 (enExample)
EP (1) EP2831077B1 (enExample)
JP (1) JP6096879B2 (enExample)
KR (1) KR102070567B1 (enExample)
CN (1) CN104169284B (enExample)
AR (1) AR090496A1 (enExample)
AU (1) AU2013242492B2 (enExample)
CA (1) CA2868620C (enExample)
CL (1) CL2014002557A1 (enExample)
CO (1) CO7111292A2 (enExample)
DK (1) DK2831077T3 (enExample)
EA (1) EA027416B1 (enExample)
EC (1) ECSP14024526A (enExample)
ES (1) ES2585044T3 (enExample)
HR (1) HRP20160908T1 (enExample)
HU (1) HUE030067T2 (enExample)
IL (1) IL234713A (enExample)
MX (1) MX351149B (enExample)
MY (1) MY172308A (enExample)
NZ (1) NZ630489A (enExample)
PE (1) PE20142186A1 (enExample)
PH (1) PH12014501829A1 (enExample)
PL (1) PL2831077T3 (enExample)
PT (1) PT2831077T (enExample)
RS (1) RS54997B1 (enExample)
SG (1) SG11201405750YA (enExample)
SI (1) SI2831077T1 (enExample)
TW (1) TWI576346B (enExample)
UA (1) UA112795C2 (enExample)
WO (1) WO2013143663A1 (enExample)
ZA (1) ZA201407828B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2822656T3 (en) 2012-03-07 2017-01-30 Inst Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
HUE030067T2 (en) 2012-03-28 2017-04-28 Merck Patent Gmbh Bicyclic pyrazinone derivatives
KR20150011838A (ko) * 2012-06-20 2015-02-02 에프. 호프만-라 로슈 아게 탄키라아제 억제제로서의 피롤로피라존
CN105722835B (zh) 2013-09-11 2018-07-31 癌症研究协会:皇家癌症医院 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
MX364859B (es) 2013-12-23 2019-05-09 Merck Patent Gmbh Derivados de imidazopirazinona.
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR101739003B1 (ko) * 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20170090476A (ko) * 2014-12-05 2017-08-07 어레이 바이오파마 인크. 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진
HK1255269A1 (zh) 2015-08-17 2019-08-09 Lupin Limited 作为parp抑制剂的杂芳基衍生物
RS60261B1 (sr) 2016-02-24 2020-06-30 Pfizer Pirazolo[1,5-a]pirazin-4-il derivativi kao jak-inhibitori
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
MX2020012201A (es) * 2018-05-17 2021-01-29 Bayer Ag Derivados sustituidos de la carboxamida dihidropirazolo pirazina.
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds
GB2632441A (en) * 2023-08-08 2025-02-12 Duke Street Bio Ltd Deuterated PARP1 inhibitor compounds
WO2025084446A1 (ko) * 2023-10-16 2025-04-24 에스티팜 주식회사 트리아졸로피리미디논 유도체의 결정형

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
EP2032140A1 (en) * 2006-05-31 2009-03-11 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
CN101616919B (zh) * 2006-12-28 2012-10-10 雅培制药有限公司 聚（adp核糖）聚合酶抑制剂
ATE542799T1 (de) 2007-03-08 2012-02-15 Janssen Pharmaceutica Nv Chinolinonderivate als parp und tank-inhibitoren
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009130232A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
WO2009130231A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
EP2350084B1 (en) 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
CA2794861A1 (en) * 2010-04-16 2011-10-20 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
CN102229611B (zh) * 2011-04-26 2012-12-12 山东大学 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用
HUE030067T2 (en) 2012-03-28 2017-04-28 Merck Patent Gmbh Bicyclic pyrazinone derivatives
KR20150011838A (ko) * 2012-06-20 2015-02-02 에프. 호프만-라 로슈 아게 탄키라아제 억제제로서의 피롤로피라존

Also Published As

Publication number Publication date
CA2868620A1 (en) 2013-10-03
KR102070567B1 (ko) 2020-01-29
TW201343650A (zh) 2013-11-01
IL234713A (en) 2016-09-29
JP2015511609A (ja) 2015-04-20
EP2831077B1 (en) 2016-04-27
HRP20160908T1 (hr) 2016-09-23
CO7111292A2 (es) 2014-11-10
SG11201405750YA (en) 2014-10-30
PE20142186A1 (es) 2014-12-29
PT2831077T (pt) 2016-08-12
NZ630489A (en) 2016-04-29
EA027416B1 (ru) 2017-07-31
SI2831077T1 (sl) 2016-09-30
MX2014011420A (es) 2014-11-25
TWI576346B (zh) 2017-04-01
MX351149B (es) 2017-10-04
US20150057264A1 (en) 2015-02-26
UA112795C2 (uk) 2016-10-25
CN104169284A (zh) 2014-11-26
ECSP14024526A (es) 2015-09-30
JP6096879B2 (ja) 2017-03-15
CA2868620C (en) 2020-02-25
ES2585044T3 (es) 2016-10-03
EP2831077A1 (en) 2015-02-04
AR090496A1 (es) 2014-11-19
US9120805B2 (en) 2015-09-01
KR20140140099A (ko) 2014-12-08
CN104169284B (zh) 2017-03-29
PL2831077T3 (pl) 2016-10-31
RS54997B1 (sr) 2016-11-30
ZA201407828B (en) 2015-12-23
PH12014501829B1 (en) 2014-11-10
MY172308A (en) 2019-11-21
EA201401062A1 (ru) 2015-04-30
HK1203961A1 (en) 2015-11-06
HUE030067T2 (en) 2017-04-28
WO2013143663A1 (en) 2013-10-03
DK2831077T3 (en) 2016-08-15
AU2013242492B2 (en) 2016-12-15
AU2013242492A1 (en) 2014-11-13
PH12014501829A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2015001702A1 (es) Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CA2956871C (en) Compounds active towards bromodomains
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
BR112014030414A2 (pt) combinação de um imunoconjugado, composição farmacêutica, uso de um imunoconjugado, métodos de tratamento e de estímulo, kit e invenção.
CL2015001250A1 (es) Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros.
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015001818A1 (es) Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras.
CL2014002358A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer.
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.